HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dc07-2306v1 31/6/1165    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Saraheimo, M. PubMed PubMed Citation Articles by Saraheimo, M. Social Bookmarking                What's this?

Serum Adiponectin and Progression of Diabetic Nephropathy in Patients With Type 1 Diabetes

¹ Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland
² Division of Nephrology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
³ Medical Department M (Diabetes and Endocrinology) and the Medical Research Laboratories, Clinical Institute, Aarhus University Hospital, Aarhus, Denmark

Corresponding author: Per-Henrik Groop, MD, DMSc, Folkhälsan Research Center, Biomedicum Helsinki (318b), Haartmaninkatu 8, P.O. Box 63, FIN-00014, University of Helsinki, Helsinki, Finland. E-mail: per-henrik.groop{at}helsinki.fi

OBJECTIVE—The purpose of this study was to elucidate whether serum adiponectin is associated with progression of diabetic nephropathy in type 1 diabetic patients.

RESEARCH DESIGN AND METHODS—This was a prospective follow-up study as a part of the nationwide Finnish Diabetic Nephropathy Study; 1,330 type 1 diabetic patients were followed for 5.0 ± 2.2 years. Patients were divided at baseline into three groups according to their urinary albumin excretion rate (AER) in three consecutive overnight or 24-h urine collections: 818 patients with normoalbuminuria (AER <20 µg/min), 216 patients with microalbuminuria (20 µg/min AER < 200 µg/min), and 296 patients with macroalbuminuria (AER 200 µg/min). Progression of albuminuria was the main outcome. Adiponectin was measured by a time-resolved immunofluorometric assay, and the values were log-transformed and adjusted for age, BMI, and sex before analysis.

RESULTS—Progression either to the next albuminuria level or to end-stage renal disease (ESRD) occurred in 193 patients. No difference in adiponectin concentrations was observed between progressors and nonprogressors in patients with normoalbuminuria or microalbuminuria. In the patients with macroalbuminuria, progression to ESRD was associated with higher adiponectin in the entire group (23.4 ± 17.1 vs. 16.0 ± 8.5 mg/l, P < 0.001) and in men (P < 0.001) and women (P < 0.001) separately. Progression to ESRD was also associated with systolic blood pressure, insulin dose, A1C, serum cholesterol, serum triglycerides, AER, and estimated glomerular filtration rate (eGFR). When these covariates were inserted in a Cox regression analysis, A1C, triglycerides, eGFR, and adiponectin were significantly associated with progression from macroalbuminuria.

CONCLUSIONS—Increased serum adiponectin levels predict the progression from macroalbuminuria to ESRD in type 1 diabetic patients.

Abbreviations: ARB, angiotensin receptor blocker • AER, albumin excretion rate • CVD, cardiovascular disease • eGFR, estimated glomerular filtration rate • ESRD, end-stage renal disease

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?